Bio Medica Lab, a company in the Pharmaceuticals industry, reported revenue of ₹22 crore and net profit of ₹3.00 crore for the September 2026 quarter.
Bio Medica Lab (NSE: BMLL-SM) closed at ₹160.70 on 20 Nov 2026. Its market capitalisation is ₹202 crore and it trades at 12.9 times earnings.
Incorporated in August 2015, Bio Medica Laboratories Ltd specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the -counter (OTC) medications
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.